Kidney-Targeted Renalase Agonist Prevents Cisplatin-Induced Chronic Kidney Disease by Inhibiting Regulated Necrosis and Inflammation.

Xiaojia GuoLeyuan XuHeino VelazquezTian-Min ChenRyan M WilliamsDaniel A HellerBarbara BurtnessRobert SafirsteinGary V Desir

Published in: Journal of the American Society of Nephrology : JASN (2021)

Kidney-targeted delivery of RNLS agonist RP81-MNP protects against cisplatin-induced CKD by decreasing cell death and improving the viability of the renal proximal tubule. These findings suggest that such an approach might mitigate the development of CKD in patients receiving cisplatin cancer chemotherapy.

Keyphrases

chronic kidney disease
end stage renal disease
cell death
papillary thyroid
oxidative stress
signaling pathway
squamous cell
cancer therapy
locally advanced
cell cycle arrest
lymph node metastasis
squamous cell carcinoma
drug delivery
radiation therapy
peritoneal dialysis
pi k akt